![Unforeseen Twists: Cue Biopharma Falls Short on EPS But Triumphs on Revenue in Q4 2023 1 CUE stock - CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600-768x432.png)
Source: iQoncept / Shutterstock
Cue Biopharma (NASDAQ:CUE) has unveiled its performance for the fourth quarter of 2023.
- Cue Biopharma fell short with earnings per share of -29 cents, slightly below the anticipated -28 cents.
- The company excelled in revenue, raking in $1.82 million, surpassing the estimated revenue of $1.71 million by 6.49%.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/04/cue-stock-earnings-cue-biopharma-for-q4-of-2023/.
©2024 InvestorPlace Media, LLC